LoadingLoadingCookies show us what works. Privacy
Cookies show us what works. Privacy
LoadingCookies show us what works. Privacy
28 funds hold it · Insiders net selling
Net selling: insiders sold $33.9M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
Unlock the full resultsLast report
Nov 3, 2026
Financial period
Q3 2026
Earnings per share
$0.72 expected
Revenue
$4.24B expected
Estimates as of Nov 10, 2026
EPS expected
$0.58 to $0.90
Revenue expected
9 analysts
Last 30 days
Analysts raising estimates
Estimate drift
Change in 30 days
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Sep 30, 2026Reported Nov 3, 2026 | $0.86est. $0.72 | +19.31%beat | $4.39Best. $4.24B+3.64% | -1.9%from $4.48B |
| Jun 30, 2026Reported Jul 29, 2026 | $0.64est. $0.05 | +$0.59beat | $4.14BSEC filing | -0.8%from $4.18B |
| Mar 31, 2026Reported Apr 29, 2026 | $0.53est. $0.46 | +15.22%beat | $3.98BSEC filing | +2.3%from $3.89B |
| Dec 31, 2025Reported Jan 28, 2026 | $0.96est. $0.64 | +50.00%beat | $1.50BSEC filing | -64.5%from $4.23B |
| Sep 30, 2025Reported Nov 5, 2025 | $0.75est. $0.66 | +13.64%beat | $4.48BSEC filing | +3.4%from $4.33B |
| Jun 30, 2025Reported Jul 30, 2025 | $0.66est. $0.62 | +6.45%beat | $4.18BSEC filing | +0.3%from $4.16B |
| Mar 31, 2025Reported May 7, 2025 | $0.52est. $0.46 | +13.04%beat | $3.89BSEC filing | +1.9%from $3.82B |
| Dec 31, 2024Reported Jan 29, 2025 | $0.71est. $0.70 | +1.43%beat | $4.23BAlpha Vantage | -5.1%from $4.46B |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $4.71B | $3.98B | $4.14B | $4.39B |
| Cost of what it sold | $2.06B | $2.01B | $1.99B | $1.96B |
| Gross profit | $2.66B | $1.97B | $2.15B | $2.44B |
| What it spent | ||||
| Research and development | $267.0M | $222.0M | $250.0M | $297.0M |
| Sales and admin | $367.0M | $304.0M | $317.0M | $298.0M |
| Other operating costs | $1.72B | $792.0M | $1.44B | $1.13B |
| Total operating expenses | $2.35B | $1.32B | $2.00B | $1.73B |
| What was left | ||||
| Operating profit | $300.0M | $652.0M | $149.0M | $714.0M |
| Interest on debt | $292.0M | $201.0M | $200.0M | $174.0M |
| Profit before tax | $91.0M | $436.0M | -$455.0M | $300.0M |
| Tax | -$390.0M | $67.0M | $121.0M | $66.0M |
| Net profit | $480.0M | $369.0M | -$576.0M | $233.0M |
| EBITDA | $632.0M | $877.0M | -$19.0M | $545.0M |
This stock is in a strong uptrend, and looks overbought after a fast run-up.
Trend
Strong uptrend
85 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
Teva Pharmaceutical Industries (NYSE:TEVA) Stock: Insider Richard Daniell Sells 20,003 Shares
Leans bullishNov 13Insider Selling: Teva Pharmaceutical Industries (NYSE:TEVA) CEO Sells $10,560,000.00 in Stock
NeutralNov 12Teva stock hits 52-week high at 43.5 USD
NeutralNov 12After a $1.07M share sale, a Teva (TEVA) executive proposes selling more.
Leans bearishNov 12Teva Pharmaceutical Industries Limited (TEVA.TA) Stock Price, News, Quote & History
BullishNov 12Teva Pharmaceutical Industries Targets Up to $7 Billion in Innovative Drug Revenue by 2030
BullishNov 12Teva CEO: We have evolved into a biopharma company
BullishNov 12Teva (TEVA) Stock Looks Undervalued Against Its Cash Flow Outlook
BullishNov 1236 macro signals shaping TEVA right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results
